This is Glenmark's second investigational new drug from its immuno-oncology portfolio to enter clinical trials.

It may be too early to forecast how Glenmark’s drugs will fare, for the next few years, the generics business will continue to be key.

Shares of Glenmark Pharmaceuticals were trading at Rs 867 in the afternoon trade, up 0.05 per cent from the previous close on BSE.